Phase II study of 2-week TS-1 administration followed by 1-week rest for gastric cancer

Hepato-Gastroenterology

Volumn 54, Issue 79, 2007, Pages 2167-2171

  Imamura, Hiroshi ^a,k   Furukawa, Hiroshi ^a   Kishimoto, Tomono ^a   Nakae, Siro ^b   Inoue, Kentaro ^c   Tsukahara, Yasuo ^d   Imano, Motohiro ^e   Yamazaki, Keiji ^f   Okano, Shinji ^g   Morimoto, Takashi ^h   Sugihara, Seiichi ⁱ   Shimokawa, Toshio ^j  

^a SAKAI MUNICIPAL HOSPITAL   (Japan)

^b SAISEIKAI NAKATSU HOSPITAL   (Japan)

^c KANSAI MEDICAL UNIVERSITY   (Japan)

^d TOYONAKA MUNICIPAL HOSPITAL   (Japan)

^e KINKI UNIVERSITY   (Japan)

^f Saiseikai Senri Hospital   (Japan)

^g MATSUSHITA MEMORIAL HOSPITAL   (Japan)

^h Yao Municipal Hospital   (Japan)

ⁱ Hoshigaoka Welfare Annuity Hospital   (Japan)

^j UNIVERSITY OF YAMANASHI   (Japan)

^k NONE   (Japan)

more..

Author keywords

2 weeks followed by a 1 week rest; Gastric cancer; TS 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; TS 1; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; FATIGUE; FEMALE; HEADACHE; HUMAN; JAPAN; LEUKOPENIA; MALE; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REST; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; SILICATES; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TITANIUM; TREATMENT OUTCOME;

EID: 37749013030     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Duschinsky R, Pleven E, Heidelberger C: The synthesis of 5-fluoropyrimidined. J Am Chem Soc Anticancer 1957; 79:4559-4560.
2. Caballero GA, Ausman RK, Quebbeman EJ: Long-term ambulatory continuous iv infusion of 5-FU for the treatment of advanced adenocarcinomas. Cancer Treat Rep 1985; 69:13-15.
3. Moynihan T, Hansen R, Anderson T, Quebbeman E, Beatty P, Ausman R, et al: Continuous 5-fluorouracil infusion in advanced gastric carcinoma. Am J Clin Oncol 1988; 11:461-464.
4. Shirasaka T, Shimamoto Y, Ohshimo H, Yamaguchi M, Kato T, Yonekuma K, et al: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996; 7:548-557.
5. Tatsumi K, Fukushima M, Shirasaka T, Fujii S: Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res 1987; 78:748-755.
6. Shirasaka T, Shimamoto Y, Fukushima M: Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 1993; 53:4004-4009.
7. Schoffski P: The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors. Anticancer Dugs 2004; 15:85-106.
8. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y and Taguchi T: Late phase II study of novel fluoropyrimidine anticancer drug S-1 (1M tegafur-0.4M gimestat-1M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998; 34:1715-1720.
9. Sugimachi K, Haehara Y, Horikoshi N, Shimada Y, Sakata Y and Mitachi Y, et al: An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. Oncology 1999; 57:202-210.
10. Nagashima F, Ohtsu A, Yoshida S, Ito K: Japanese nationwide postmarketing survey of S-1 in patients with advanced gastric cancer. Gastric Cancer 2005; 8:6-11.
11. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al: New guidelines to evaluate the response to treatment in solid tumors. J Nat Cancer Inst 2000; 92:205-216.
12. Kimura Y, Kikkawa N, Iijima S, Kato T, Naoi Y, Hayashi T, et al: A new regimen for S-1 therapy aiming at adverse reaction mitigating and prolonged medication by introducing a 1-week drug-free interval after each 2-week dosing session: efficacy and feasibility in clinical practice. Gastric Cancer 2003; 6(Suppl 1):31-39.
13. Tsukuda M, Kida A, Fujii M, Kono T, Yoshihara T, Hasegawa Y, et al: Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer. Br J Cancer 2005; 93:884-889.